<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="critically ill patients. A set of approved marketed drugs like" exact="hydroxychloroquine" post="(HCQ) [11, 12], chloroquine (CLQ) [12], combination of HCQ"/>
 <result pre="set of approved marketed drugs like hydroxychloroquine (HCQ) [11, 12]," exact="chloroquine" post="(CLQ) [12], combination of HCQ and azithromycin [13], remdesivir"/>
 <result pre="(HCQ) [11, 12], chloroquine (CLQ) [12], combination of HCQ and" exact="azithromycin" post="[13], remdesivir [14], lopinavir [15] and ritonavir [15] are"/>
 <result pre="(CLQ) [12], combination of HCQ and azithromycin [13], remdesivir [14]," exact="lopinavir" post="[15] and ritonavir [15] are being evaluated for the"/>
 <result pre="of HCQ and azithromycin [13], remdesivir [14], lopinavir [15] and" exact="ritonavir" post="[15] are being evaluated for the infection treatment; their"/>
 <result pre="(AT1R) blockers, antiviral drugs, antimalarial drugs, interferon, IL-6 inhibitors, corticosteroids," exact="ascorbic acid," post="some antibacterial antibiotics, etc. An up-to-date list of drugs"/>
 <result pre="(SCCM) Surviving Sepsis Campaign recommended the routine use of lopinavir;" exact="ritonavir" post="in critically ill adults Darunavir/darunavir + cobicistat [Prezcobix] [65] (antiviral) Shanghai"/>
 <result pre="repurposing only in combination with other drugs like ASC09F and" exact="ritonavir" post="No trials on COVID-19 yet. Due to lack of"/>
 <result pre="treat severe disease in COVID-19 patients Initial analysis suggests that" exact="tocilizumab" post="may have a clinical advantage as an adjunctive therapy"/>
 <result pre="immune cells like CD4 cells (1) Leronlimab in combination with" exact="carboplatin" post="can be used for the treatment of CCR5-positive metastatic"/>
 <result pre="a result of Covid-19 EUSA Pharma initiates the study of" exact="siltuximab" post="to treat Covid-19 patients Based on the clinical data,"/>
 <result pre="the clinical data, the company reported that 16 patients using" exact="siltuximab" post="were stable or had improved disease at the interim"/>
 <result pre="[88] University of Palermo T-lymphocytes (1) Recent studies showed that" exact="ascorbic acid" post="(vitamin C) clearly affects the development and maturation of"/>
 <result pre="Galidesivir (developed by BioCryst Pharmaceuticals; preclinical stage), Combination of ebastine," exact="lopinavir" post="and interferon alpha (developed by Wuhan Red Cross Hospital;"/>
 <result pre="cleaved by some of proteases like 3CLpro, PLpro, etc. (lopinavir," exact="ritonavir" post="and darunavir act as inhibitors of this step) to"/>
 <result pre="some of proteases like 3CLpro, PLpro, etc. (lopinavir, ritonavir and" exact="darunavir" post="act as inhibitors of this step) to form RNA"/>
 <result pre="responsible for replication of structural protein RNA. (Remdesivir, favilavir and" exact="ribavirin" post="act as inhibitors of this enzyme). Structural proteins S1,"/>
 <result pre="receptor and partial agonists of AT2 receptor; losartan, valsartan, irbesartan," exact="candesartan" post="cilexetil, telmisartan, and eprosartan (FDA-approved AT1 receptor blockers)] may"/>
 <result pre="of AT2 receptor; losartan, valsartan, irbesartan, candesartan cilexetil, telmisartan, and" exact="eprosartan" post="(FDA-approved AT1 receptor blockers)] may be used as important"/>
 <result pre="[42]. A recent in vitro data showed that remdesivir and" exact="chloroquine" post="(CQ) phosphate are capable of inhibiting SARS-CoV-2 infection [14]."/>
 <result pre="4, 2020, and in the USA. Chloroquine/hydroxychloroquine Chloroquine (CLQ) and" exact="hydroxychloroquine" post="(HCQ) have received deep attention because of positive results"/>
 <result pre="candidate against SARS-CoV-2. This drug is less toxic (~ 40%) than" exact="chloroquine" post="in animals. It was found that there were seven"/>
 <result pre="mass-produced as generic version in China [45, 46]. Ritonavir and" exact="lopinavir" post="(Kaletra) These drugs are approved HIV-1 protease inhibitors, used"/>
 <result pre="These nsps are essential for viral RNA synthesis. Ritonavir and" exact="lopinavir" post="act by inhibiting these protease enzymes. The mechanisms of"/>
 <result pre="Wuhan, China, using lopinavir–ritonavir against Arbidol hydrochloride (influenza drugs) and" exact="oseltamivir" post="(NCT04255017). In South Korea, a comparative study of lopinavir–ritonavir"/>
 <result pre="is depicted in Fig. 9. Recently, several monoclonal antibodies, namely" exact="tocilizumab" post="(atlizumab), mavrilimumab, lenzilumab, leronlimab, gimsilumab, sarilumab, siltuximab (Sylvant), camrelizumab"/>
 <result pre="monoclonal antibodies, namely tocilizumab (atlizumab), mavrilimumab, lenzilumab, leronlimab, gimsilumab, sarilumab," exact="siltuximab" post="(Sylvant), camrelizumab (AiRuiKa), eculizumab (Soliris), etc., are being tried"/>
 <result pre="(atlizumab), mavrilimumab, lenzilumab, leronlimab, gimsilumab, sarilumab, siltuximab (Sylvant), camrelizumab (AiRuiKa)," exact="eculizumab" post="(Soliris), etc., are being tried to investigate their potency"/>
 <result pre="such as ACE inhibitors including benazepril/lisinopril, birth control pills containing" exact="drospirenone" post="Mild: Dizziness, chest pain, hypoglycemia Serious: Hyperkalemia, hypotension, and"/>
 <result pre="Spike protein through docking. This was followed by screening of" exact="artemisinin" post="derived compounds to show better docking score (two mode"/>
 <result pre="study followed by VS (AutoDock 4.2) Four pharmacophores (OEW, remdesivir," exact="hydroxychloroquine" post="and N3) and 50,000 natural compounds from ZINC database"/>
 <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
 <result pre="molecular modeling studies reveal a new mechanism of action of" exact="chloroquine" post="and hydroxychloroquine against SARS-CoV-2 infectionInt J AntiMicrob Agents20205510596010.1016/j.ijantimicag.2020.10596032251731 13.GautretPLagieracJ-CParolaPet"/>
 <result pre="studies reveal a new mechanism of action of chloroquine and" exact="hydroxychloroquine" post="against SARS-CoV-2 infectionInt J AntiMicrob Agents20205510596010.1016/j.ijantimicag.2020.10596032251731 13.GautretPLagieracJ-CParolaPet al.Clinical and"/>
 <result pre="Agents20205510596010.1016/j.ijantimicag.2020.10596032251731 13.GautretPLagieracJ-CParolaPet al.Clinical and microbiological effect of a combination of" exact="hydroxychloroquine" post="and azithromycin in 80 COVID-19 patients with at least"/>
 <result pre="al.Clinical and microbiological effect of a combination of hydroxychloroquine and" exact="azithromycin" post="in 80 COVID-19 patients with at least a six-day"/>
 <result pre="a pilot observational studyTravel Med Infect Dis20203410166332289548 14.WangMCaoRZhangetLet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
 <result pre="novel coronavirus in the United StatesN Engl J Med202038292993632004427 43.GaoJTianZYangXBreakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
 <result pre="associated pneumonia in clinical studiesBiosci Trends202014727332074550 44.Al-BariMAATargeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
 <result pre="Elsevier (2020) https://www.elsevier.com/__data/assets/pdf_file/0010/990730/Lopinavir,-Ritonavir-Drug-Monograph_3.17.2020.pdf. Accessed 11 May 2020 49.CalyLDruceJDCattonMGJansDAWagstaffKMThe FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntivir Res202017810478732251768 50.WagstaffKMRawlinsonSMHearpsACJansDAAn"/>
 <result pre="Science Times. https://www.sciencetimes.com/articles/25053/20200317/favilavir-first-approve-drug-treat-coronavirus.htm. Accessed 11 May 2020 61.Favipiravir combined with" exact="tocilizumab" post="in the treatment of Corona Virus Disease 2019. ClinicalTrials.gov."/>
 <result pre="Omega202058312832032363255 111.Sehailia M, Chemat S (2020) In-silico studies of antimalarial-agent" exact="artemisinin" post="and derivatives portray more potent binding to Lys353 and"/>
 <result pre="molecular modelling studies reveal a new mechanism of action of" exact="chloroquine" post="and hydroxychloroquine against SARS-CoV2 infectionInt J Antimicrob Agents202010.1016/j.ijantimicag.2020.10596032862840 113.Srivastava"/>
 <result pre="studies reveal a new mechanism of action of chloroquine and" exact="hydroxychloroquine" post="against SARS-CoV2 infectionInt J Antimicrob Agents202010.1016/j.ijantimicag.2020.10596032862840 113.Srivastava A, Singh"/>
</results>
